ID   GL-40
AC   CVCL_C0Q1
DR   Wikidata; Q112929584
RX   PubMed=23363222;
RX   PubMed=24975508;
CC   Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
CC   Breed/subspecies: German Shepherd; VBO=VBO_0200577.
DI   NCIt; C128120; Canine leukemia
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
HI   CVCL_L352 ! GL-1 [Dog leukemia]
SX   Male
AG   9Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 19-12-24; Version: 6
//
RX   PubMed=23363222; DOI=10.1111/jvp.12039;
RA   Zandvliet M., Teske E., Chapuis T., Fink-Gremmels J., Schrickx J.A.;
RT   "Masitinib reverses doxorubicin resistance in canine lymphoid cells by
RT   inhibiting the function of P-glycoprotein.";
RL   J. Vet. Pharmacol. Ther. 36:583-587(2013).
//
RX   PubMed=24975508; DOI=10.1016/j.tiv.2014.06.004;
RA   Zandvliet M., Teske E., Schrickx J.A.;
RT   "Multi-drug resistance in a canine lymphoid cell line due to increased
RT   P-glycoprotein expression, a potential model for drug-resistant canine
RT   lymphoma.";
RL   Toxicol. In Vitro 28:1498-1506(2014).
//